Figure S7 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis | Synapse
August 4, 2025
Figure S7 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis
Puntos clave
MAIN FINDING: A humanized CD36-blocking antibody effectively enhances antitumor immunity against liver cancer.
KEY EVIDENCE: The immune profile assessed indicates significant improvements in tumor immunity following treatment.
APPROACH: A specific gating strategy was utilized to analyze the immune responses in human HCC tumor tissues.
SIGNIFICANCE: This research suggests that targeting CD36 may provide new therapeutic strategies for liver cancer and metastasis.
Resumen
Gating Strategy employed to assess the immune profile in human HCC tumor tissue.